Cargando...
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism
Edoxaban, a factor Xa inhibitor, was approved by the United States Food and Drug Administration in 2015 for stroke prevention in nonvalvular atrial fibrillation and treatment of venous thromboembolism. It is the fourth target-specific oral anticoagulant to be approved. Edoxaban is noninferior for ef...
Gardado en:
| Publicado en: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4853158/ https://ncbi.nlm.nih.gov/pubmed/27217759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S84608 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|